Study details
Enrolling now
Clinical Trial on Agitation in Alzheimer's Dementia
IGC Pharma, LLC
NCT IDNCT05543681ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
164
Study length
about 3.5 years
Ages
60+
Locations
22 sites in FL, LA, MD +6
About this study
Researchers are testing whether a new medication, IGC-AD1, helps reduce agitation in people with Alzheimer's disease. The trial will last for 1266 days and involve approximately 164 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take IGC-AD1-Active
- 2.Take IGC-AD1-Placebo
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Neurology